Artificial oxygen carriers as an alternative to allogenic blood transfusion: success and challenges
DOI:
https://doi.org/10.53704/Keywords:
Artificial oxygen carriers, perfluorocarbon, fluorosol-DA, perftoan and dodecafluoropentaneAbstract
Artificial blood, also referred to as artificial oxygen carriers, is a blood substitute or an alternative to blood/blood products that can perform the most indispensable activities of blood, which are the transportation of oxygen and carbon dioxide. Artificial oxygen carriers could be a daily living support measure, particularly during serious blood loss in disasters; however, the products currently being developed can't provide the additional components of blood, such as immune support. The main indications for the clinical use of artificial oxygen carriers include cardiovascular surgery, elective surgery, trauma, perfusion of ischemic tissue, organ preservation, drug carriers, and oxygenation of solid tumours. Desirable qualities of artificial oxygen carriers included the absence of adverse effects and pathogens, in addition to oxygen transport; they can effectively deliver oxygen to tissues, have a long shelf life at room temperature, require no pre-requisite of cross-matching, blood grouping and Compatibility tests, and survive in circulation for a considerable time. The major types of artificial oxygen carriers include perfluorocarbons, fluorosol-DA, perftoan and dodecafluoropentane. Data were collected from PubMed, Google Scholar, Taylor & Francis, MDPI, Springer, Nature, BMC, and other related sources. In this review, the details of artificial oxygen carriers and the successes and challenges of using them as an alternative to allogenic blood transfusion were thoroughly analysed.
References
1. Henkel T, Oleck M. Artificial oxygen carriers: A current review. Artificial oxygen carrier’s journal. 2007; 75(3); 205–211.
2. Kresie L. Artificial blood: An update on current red cell and platelet substitutes. Bayelsa. University Medical Centre. 2016; 14(2), 158-161.
3. Haldar R, Gupta D, Chitranshi S, Singh MK, Sachan S. Artificial Blood: A Futuristic Dimension of Modern Day Transfusion Sciences. Cardiovascular Haematology. 2019; 17(1); 11-16.
4. Amberson WR, Jennings JJ, Rhode CM. Clinical experience with haemoglobin- saline solutions. Journal of Applied Physiology. 2019; 1(7): 469-489.
5. Squires JE. Artificial blood. Journal of Science.2019; 295(5557): 1002-1005.
6. Shander A, Alalawi R, Seeber P, Lui J. Use of a hemoglobin-based oxygen carrier in the treatment of severe anaemia. Obstetric Gynecology. 2014; 103(2): 1096-1099.
7. Sharma R, Kashyap M, Zayed H. et al. Artificial blood—hope and the challenges to combat tumor hypoxia for anti-cancer therapy. Medical and Biological Engineering and Computing. 63, 933–957 (2025). https://doi.org/10.1007/s11517-024-03233-6.
8. Pape A, Habler O. Alternatives to allogeneic blood transfusions. Best Practice Resident Clinical Anaesthesiology. 2017; 21(2): 221-239.
9. Smani Y. Hemospan. A hemoglobin-based oxygen carrier for potential use as a blood substitute and for the potential treatment of critical limb ischemia. Current Opinion on investigation of Drugs. 2018; 9(5): 1009–1019.
10. Sakai H, Horinouchi H, Tomiyama K. Haemoglobin-vesicles as oxygen carriers: influence on phagocytic activity and histopathological changes in reticuloendothelial system. Journal of Pathology. 2016; 159(3): 1079–1088.
11. Sarkar S. Artificial blood. Indian Journal Criteria Care Medicine. 2018; 12(3) 140-144.
12. Scott MG, Kucik DF, Goodnough LT, Monk TG. Bloodsubstitutes: Evolution and future applications. Clinical Chemistry. 2020; 43(9) 1724-1731.
13. Farrar D, Grocott M. Intravenous artificial oxygen carriers. Hospital. Medical Journal. 2019; 64(6), 352-356.
14. Jägers J, Wrobeln A, Ferenz KB. Perfluorocarbon-based oxygen carriers: from physics to physiology. Pflugers Arch - European Journal of Physiology. 2021; 473, 139–150. https://doi.org/10.1007/s00424-020-02482-2
15. Nishimura N, Nitsuno T, Naito R. Clinical studies of a perfluorochemical, whole blood substitute. Critical Care Medicine. 2021; 9(3): 168.
16. Chang TM. Haemoglobin-based red blood cell substitutes. Artificial Organs. 2016a; 28(9):789-794.
17. Chang, S. Blood substitutes based on nanobiotechnology. Trends Biotechnology. 2016b; 24(8): 372-377.
18. Clark LC, Gollan F. Survival of mammals breathing organic liquids equilibrated with oxygen at atmospheric pressure. Journal of Science.2017; 152(7): 1755-1756.
19. Zhengwen Z, Wilson P, Daugherty P, Dong S, Joseph E, Levasseur NA, Robert J, Hamm C, Gaylan L, Rockswold M, Ross B. Protection of mitochondrial function and improvement in cognitive recovery in rats treated with hyperbaric oxygen following lateral fluid-percussion injury. Journal of neurosurgery. 2017; 106(4): 687-694.
20. Gary W, Latson N. Perftoran (Vidaphor)-Introduction to Western Medicine. Journal of Medicine. 2019; 5(2): 65-69.
21. Kaitlin G, Paula F, Moon-Massat EC. Dodecafluoropentane Emulsion as a Resuscitation Fluid for Treatment of Hemorrhagic Shock and Traumatic Brain Injury. Review of Journal of medicine. 2019; 8(12): 50-54.
22. Jennifer LH, Johnson N. Oxygen Carriers: Are They Enough for Cellular Support, Neuroprotective Therapy for Stroke and Ischemic Disease. Springer International Publishing Switzerland. 2017; 12(8) 621-640.
23. Ryan L, Sheppard S, David P, Regis N, Richard T, Mahon T. Dodecafluoropentane (DDFPe) and decompression sickness-related mortality in rats”, Aerospace medicine and human performance.2015; 8(11): 21-26.
24. Lui F, Kluger R. Reviving artificial blood: meeting the challenge of dealing with no scavenging by hemoglobin. Journal of Chemical biochemistry. 2010; 11(13): 1816–1824.
25. Veronese FM, Pasut G. PEGylation, successful approach to drug delivery. Drug Discovery Today.2005; 10 (21): 1451-1458.
26. Jahr JS, Nesargi SB, Lewis K, Johnson C. Blood substitutes and oxygen therapeutics: an overview and current status. Journal of Artificial Therapy. 2022; 9(5): 437-443.
27. Hill SE. Oxygen therapeutics-current concepts. Journal of Aanesthesia. 2021; 48(4): 32-40.
28. Nijaya M, Himangsu M, Young-Joon P, Jun-Pil J. Therapeutic delivery of oxygen using artificial oxygen carriers demonstrates the possibility of treating a wide range of diseases. Journal of Nanobiotechnology. 2025; 23(1). DOI:10.1186/s12951-024-03060-9
29. Spahn DR, Kocian R. Artificial O2 carriers. Journal of Pharmacy. 2018; 11(31): 4099-4114.
30. Fontes PA. The evolution of oxygen carrier solutions for machine perfusion. Jounal of Transplantation. 2017; 101(11): 2657-2658.
31. Creteur J, Vincent JL. Haemoglobin solutions. Critical Care Medicine. 2016; 31(12): S698-S707.
32. Kim HW, Greenburg AG. Artificial oxygen carriers as red blood cell substitutes: a selected review and current status. Artificial Organs. 2004; 28(9): 813-28. doi: 10.1111/j.1525-1594.2004.07345.x.
Downloads
Published
Issue
Section
License
Copyright (c) 2025 IBRAHIM KALLE KWAIFA, Ukashat Bello Bunza
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain copyright of their work, with first publication rights granted to Fountain Journal of Natural and Applied Sciences. Articles in FUJNAS are published on the Creative Commons Attribution 4.0 International license (CC BY 4.0).
